Perkins Coie Advises Xentria in Multi-Year Licensing Agreement with Meitheal to Market Xentria’s Novel Biologic to Treat Pulmonary Sarcoidosis

CHICAGO (July 11, 2023)—Perkins Coie is pleased to have advised Xentria Inc., a clinical-stage biotherapeutics company dedicated to developing novel therapeutics to address unmet medical needs, in its exclusive multi-year licensing agreement with Meitheal Pharmaceuticals, Inc., to commercialize its novel biologic XTMAB-16 for pulmonary sarcoidosis in North America.

The Perkins Coie team was led by Chicago-based Corporate & Securities Partner John Schreiner and Intellectual Property Partner David Fournier, who serves as chair of the firm's Patent Prosecution & Portfolio Counseling practice, and also included San Diego Partner Mark Wicker, Chicago Partner Sarah Flotte, Seattle Counsel Allison Glasunow, and San Diego Associate Alina Litoshyk.

In a deal valued in excess of $600 million, Meitheal will obtain sole rights to market the biologic in North America, with Xentria continuing to oversee its clinical development and maintaining the rights to market the product in all other countries subject to a right of first offer.

XTMAB-16, a lead candidate of Xentria and an anti-TNFα monoclonal antibody, will be tested in Phase II clinical trials later this year to analyze its ability to reduce an inflammatory response related to pulmonary sarcoidosis.